Nektar Therapeutics (NKTR) Nasdaq Global Select
36.970.541.48%
CloseDecember 12, 2018

News: updated – 12-Dec 08:27


Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit against Nektar Therapeutics, Inc.12-Dec 06:48(Business Wire)

Law Offices of Howard G. Smithreminds investors of the December 31, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Nektar Therapeutics, Inc. (Nektar or the Company) (NASDAQ: NK…

Affimed: Positive Takeaways From AFM-13 Focused R&D Day; Multiple Catalysts Ahead Including Potential Partnership With PD1/PD-L1 Company For AFM13 Combo Trial12-Dec 10:29(SeekingAlpha)

As the previous article provided a broad overview of Affimed and the opportunity for investors , this follow-up will concentrate almost exclusively on takeaways from the AFM13-focused R&D Day. Extreme market weakness on the R&D day overshadowed a positive event for Affimed ( AFMD ) …